Strategic leader and scientist blending >15 years of oncology R&D with two decades worth of deep expertise in Advanced Cell Models (ACMs), Microphysiological Systems (MPS), Complex In Vitro Models (CIVMs) and organoids to replace/refine traditional preclinical approaches with human-relevant models. Strong contributor to data standardisation and FAIR principles, working at the interface of biology, data science, and regulatory policy. Adept at leading global cross-functional, cross-sector collaborations and integrating cutting-edge ACMs (including organoids, MPS, and in silico approaches) into decision-making frameworks across drug discovery and safety assessment. KEY SKILLS & EXPERTISE • Defining and executing ACM strategies for drug discovery and development • Innovation in human-relevant complex in vitro models (3D spheroids, organ-on-chip, organoids, 3D bioprinting) for pharmaceutical setting • Champion of 3Rs through the implementation of ACMs and their regulatory acceptance through strong communication with regulatory bodies • Adept with FAIR principles and cross-enterprise data alignment strategies (e.g., ISO, OECD) • Automation, scaling & efficient data management in advanced cell models • Strategic partnerships with pharma, biotech, academia, and CROs • Global consortia leadership (EUROOCS IAB Chair, IQ-MPs, NC3Rs, 3RsC) • Cross-functional team building, matrix leadership